Overview
Sudarshan Pharma Industries Limited announced that its Board has approved a strategic investment to acquire a 9.50% equity stake in MedTherapy Biotechnology Inc., a United States‑based biotechnology firm developing integrated CAR‑T cell therapy and contract development and manufacturing capabilities. The transaction will be funded in cash denominated in US dollars and is intended to accelerate Sudarshan Pharma’s global expansion and diversification into advanced oncology and cell‑and‑gene therapy.
Promoter Participation
In addition to the corporate stake, the company’s promoters, Chairman and Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta, have each separately proposed to acquire a 1.50% equity interest in MedTherapy Biotechnology. Combined with the company’s 9.50% holding, the total proposed interest of Sudarshan Pharma and its two promoters would amount to 12.50% of the target entity.
Strategic Rationale
The proposed investment is positioned as a platform that merges US‑based innovation in CAR‑T and related biotechnologies with cost‑efficient manufacturing capacity in India. Sudarshan Pharma expects the partnership to provide access to the US biotechnology market, enable participation in advanced oncology, and create a scalable global business covering technology development, manufacturing, licensing, commercialisation, and patient access. The board described the move as a “bold and potentially transformative step” in the company’s growth journey, expanding its existing pharmaceutical, specialty‑chemical, contract‑manufacturing and healthcare‑solution businesses into higher‑technology, innovation‑led healthcare segments.
Transaction Conditions and Timeline
The acquisition is subject to completion of legal, financial, commercial and technical due diligence, execution of definitive agreements, receipt of all applicable regulatory approvals and compliance with overseas‑investment regulations. The parties have targeted 31 March 2027 as the expected closing date, contingent upon fulfillment of the aforementioned conditions.
Quotes
Hemal Mehta, Chairman and Managing Director, stated that the investment would strengthen Sudarshan Pharma’s presence in the United States and allow entry into a modern healthcare area characterised by significant unmet medical needs and international market potential. Sachin Mehta, Joint Managing Director, highlighted the potential to build a scalable global business and generate sustainable shareholder value through the combined technology, manufacturing, market access and commercialisation platform.
Disclaimer
The press release is provided under an arrangement with PNN. PTI takes no editorial responsibility for the content.